环孢素A免疫抑制剂治疗慢性肾小球肾炎的临床分析  

Clinical Analysis of Cyclosporine A Immunosuppressant in the Treatment of Chronic Glomerulonephritis

作　　者：樊佳佳 FAN Jiajia(Department of Nephrology,Anyang People's Hospital,Anyang Henan 455000,China)

机构地区：[1]安阳市人民医院肾内科,河南安阳455000

出　　处：《临床研究》2024年第11期39-42,共4页Clinical Research

摘　　要：目的探究慢性肾小球肾炎(CGN)的临床治疗应用环孢素A免疫抑制剂的价值。方法选取2020年10月至2023年10月安阳市人民医院肾内科诊治的62例CGN病例,依据用药计划的差异,将其分为研究组(n=31,环孢素A+常规泼尼松治疗)、对照组(n=31,常规泼尼松治疗),分析其在临床疗效、肾功能指标,细胞血清因子方面的差异。结果治疗后,研究组治疗有效率(96.77%)显著高于对照组(70.97%),差异有统计学意义(P<0.05);治疗前两组肾功能指标差异无统计学意义(P>0.05);治疗后,研究组24 h尿蛋白定量(24 h UPR)、尿素氮(BUN)、血肌酐(SCr)水平均低于对照组,差异有统计学意义(P<0.05);治疗前两组血清细胞因子指标差异无统计学意义(P>0.05);治疗后,研究组可溶性血管内皮生长因子受体-1(sFIt-1)、溶酶体关联膜蛋白-2(LAMP-2)、Ⅰ型纤溶酶原激活物抑制剂(PAI-1)、白介素-17(IL-17)水平均低于对照组,差异有统计学意义(P<0.05)。结论应用环孢素A免疫抑制剂结合泼尼松治疗CGN,能够显著提升临床疗效,强化肾功能,降低患者血清细胞因子水平,值得临床应用。Objective To explore the clinical value of using Cyclosporine A immunosuppressant in the treatment of chronic glomerulonephritis(CGN).Methods A total of 62 CGN cases treated at Anyang People's Hospital from October 2020 to October 2023 were selected.The patients were divided into a study group(n=31,treated with Cyclosporine A combined with conventional prednisone)and a control group(n=31,treated with conventional prednisone).The clinical efficacy,renal function indicators,and serum cytokine levels were analyzed and compared between the two groups.Results After treatment,the study group had a significantly higher treatment effective rate(96.77%)compared to the control group(70.97%),with statistical significance(P<0.05).There were no significant differences in renal function indicators between the two groups before treatment(P>0.05).After treatment,the 24-hour urine protein quantification(24h UPR),blood urea nitrogen(BUN),and serum creatinine(SCr)levels in the study group were significantly lower than those in the control group(P<0.05).Before treatment,there were no significant differences in serum cytokine levels between the two groups(P>0.05).After treatment,the levels of soluble vascular endothelial growth factor receptor-1(sFlt-1),lysosome-associated membrane protein-2(LAMP-2),plasminogen activator inhibitor-1(PAI-1),and interleukin-17(IL-17)in the study group were significantly lower than those in the control group(P<0.05).Conclusion The combination of Cyclosporine A and prednisone in the treatment of CGN can significantly improve clinical efficacy,enhance renal function,and reduce serum cytokine levels,making it worthy of clinical application.

关 键 词：环孢素A免疫抑制剂 慢性肾小球肾炎 疗效 肾功能 

分 类 号：R692.3[医药卫生—泌尿科学]